ArticlePharmaceutics2025

Development of Low-Dose Disulfiram Rectal Suppository Intended for Application in Post-Treatment Lyme Disease Syndrome.

Beáta-Mária Benkő et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.